American Journal of Cardiology
Volume 105, Issue 8 , Pages 1090-1094 , 15 April 2010

Importance of Measuring Glycosylated Hemoglobin in Patients With Myocardial Infarction and Known Diabetes Mellitus

  • Joshua M. Stolker, MD

      Affiliations

    • St. Luke's Mid America Heart Institute, Kansas City, Missouri
    • University of Missouri–Kansas City, Kansas City, Missouri
    • Corresponding Author InformationCorresponding author: Tel: 816-932-5475; fax: 816-932-5613
    • ,
  • Dazhong Sun, MD

      Affiliations

    • St. Luke's Mid America Heart Institute, Kansas City, Missouri
    • University of Missouri–Kansas City, Kansas City, Missouri
    • ,
  • Darcy G. Conaway, MD

      Affiliations

    • University of Missouri–Kansas City, Kansas City, Missouri
    • ,
  • Philip G. Jones, MS

      Affiliations

    • St. Luke's Mid America Heart Institute, Kansas City, Missouri
    • ,
  • Frederick A. Masoudi, MD, MSPH

      Affiliations

    • University of Colorado, Aurora, Colorado
    • Denver Health Medical Center, Denver, Colorado
    • ,
  • Pamela N. Peterson, MD, MSPH

      Affiliations

    • University of Colorado, Aurora, Colorado
    • ,
  • Harlan M. Krumholz, MD, SM

      Affiliations

    • Yale University, New Haven, Connecticut
    • ,
  • Mikhail Kosiborod, MD

      Affiliations

    • St. Luke's Mid America Heart Institute, Kansas City, Missouri
    • University of Missouri–Kansas City, Kansas City, Missouri
    • ,
  • John A. Spertus, MD, MPH

      Affiliations

    • St. Luke's Mid America Heart Institute, Kansas City, Missouri
    • University of Missouri–Kansas City, Kansas City, Missouri

Received 1 August 2009 ,Revised 1 December 2009 ,Accepted 1 December 2009.

References 

  1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  2. Morocutti G The BARI Investigators. Bypass treatment is better than angioplasty in reducing long-term mortality in diabetic patients with multivessel coronary disease [article in Italian]. Ital Heart J. 2000;1(suppl):951–952
  3. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2652–2658
  4. Berger PB, Velianou JL, Aslanidou Vlachos H, Feit F, Jacobs AK, Faxon DP, et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy (Results from the Bypass Angioplasty Revascularization Investigation (BARI)). J Am Coll Cardiol. 2001;38:1440–1449
  5. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765–775
  6. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57–65
  7. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650–661
  8. Standards of medical care in diabetes—2008. Diabetes Care. 2008;31(suppl):S12–S54
  9. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351–357
  10. Werner RM, Greenfield S, Fung C, Turner BJ. Measuring quality of care in patients with multiple clinical conditions: summary of a conference conducted by the Society of General Internal Medicine. J Gen Intern Med. 2007;22:1206–1211
  11. Spertus JA, Peterson E, Rumsfeld JS, Jones PG, Decker C, Krumholz H. The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)—evaluating the impact of myocardial infarction on patient outcomes. Am Heart J. 2006;151:589–597
  12. Standards of medical care in diabetes. Diabetes Care. 2005;28(suppl):S4–S36
  13. Gerstein HC. Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med. 2004;141:475–476
  14. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–778
  15. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078–3086
  16. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med. 2004;164:982–988
  17. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–1367
  18. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004;291:335–342
  19. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559
  20. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572
  21. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  22. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  23. Fonarow GC. In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits. Chest. 2005;128:3641–3651
  24. Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J. 2005;149:984–993
  25. Fonarow GC. When to initiate beta-blockers in heart failure: is it ever too early?. Curr Heart Fail Rep. 2005;2:94–99
  26. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611–616
  27. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135:825–834
  28. Conaway DG, O'Keefe JH, Reid KJ, Spertus J. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol. 2005;96:363–365
  29. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140–2144

 This work was supported by Grant P50 HL077113 from the National Heart, Lung, and Blood Institute Specialized Center for Clinically Oriented Research in Cardiac Dysfunction and Disease, Bethesda, Maryland. The Prospective Registry Evaluating Myocardial Infarction Patients: Events and Recovery–Quality Improvement (PREMIER-QI) was sponsored primarily by CV Therapeutics (Palo Alto, California), which had no role in study design, data analysis or interpretation, or drafting and approving this report.

PII: S0002-9149(09)02838-0

doi: 10.1016/j.amjcard.2009.12.010

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1090-1094 , 15 April 2010

Article Tools

* Image Usage & Resolution